Law360, New York (March 12, 2013, 6:18 PM ET) -- Bankrupt drugmaker KV Pharmaceutical Co. asked the D.C. Circuit on Monday to allow court review of a U.S. Food and Drug Administration statement soliciting compounded versions of prenatal medicine Makena, saying the agency’s active encouragement of competing products doesn’t merit deference.
Subscription required here